secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066969
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Janux Q1 net loss $23.5M; initiates JANX007 Phase 1b expansion in mCRPC
-----------------------------------------------------------------------

- Initiated Phase 1b expansion with JANX007 in taxane-naïve mCRPC; updated median rPFS 7.5 months (n=16).
- Cash and equivalents $1.01B at March 31, 2025, down from $1.03B at Dec 31, 2024.
- R&D expenses $25.1M (Q1 2025) vs $14.1M (Q1 2024); net loss $23.5M vs $14.8M.
- Additional JANX007 and JANX008 data expected in H2 2025; R&D Day planned mid-2025.
- Selected two dose regimens (0.3/2/6mg and 0.3/2/9mg) for Phase 1b expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017025066969/0000950170-25-066969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017025066969/janx-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer